{"title":"炎症生物标志物、高尿酸血症与慢性肾脏疾病的关系:NHANES 2015-2020分析","authors":"Huimin Li, Jingda Huang, Mindan Sun","doi":"10.1080/0886022X.2025.2553808","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Inflammation and hyperuricemia are closely associated with chronic kidney disease (CKD). The systemic inflammation response index (SIRI), systemic immune-inflammation index (SII), monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are emerging as novel biomarkers. While, the synergistic effects of these biomarkers with hyperuricemia on CKD remain unclear.</p><p><strong>Method: </strong>We analyzed 10,226 participants from 2015-2020 National Health and Nutrition Examination Survey (NHANES). The relationships among inflammatory biomarkers (SIRI, SII, MLR, NLR, and PLR), hyperuricemia and CKD were assessed by multivariate logistic regression models. Restricted cubic splines (RCS) and segmented regression models were used to evaluate the nonlinear relationships. The diagnostic performance was evaluated using receiver operating characteristic (ROC) curve, and incremental predictive value was further calculated by Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI). The interaction analysis was performed to explore the combined effects.</p><p><strong>Results: </strong>SIRI, SII, MLR, and NLR were significantly linked with CKD. MLR exhibited a threshold effect at 0.22 (<i>p</i>-non-linear < 0.05), with significantly stronger association with CKD above this cutoff. SIRI demonstrated the best diagnostic accuracy among these biomarkers. Significant interactions were observed between hyperuricemia and inflammatory biomarkers (SIRI, SII, MLR, NLR), indicating that the association between inflammatory biomarkers and CKD is more pronounced in the presence of hyperuricemia.</p><p><strong>Conclusion: </strong>There were significant associations between inflammatory biomarkers (SII, SIRI, NLR, MLR) and CKD, with particularly stronger correlations observed in patients with hyperuricemia.</p>","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2553808"},"PeriodicalIF":3.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416012/pdf/","citationCount":"0","resultStr":"{\"title\":\"The relationship among inflammatory biomarkers, hyperuricemia and chronic kidney disease: analysis of the NHANES 2015-2020.\",\"authors\":\"Huimin Li, Jingda Huang, Mindan Sun\",\"doi\":\"10.1080/0886022X.2025.2553808\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Inflammation and hyperuricemia are closely associated with chronic kidney disease (CKD). The systemic inflammation response index (SIRI), systemic immune-inflammation index (SII), monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are emerging as novel biomarkers. While, the synergistic effects of these biomarkers with hyperuricemia on CKD remain unclear.</p><p><strong>Method: </strong>We analyzed 10,226 participants from 2015-2020 National Health and Nutrition Examination Survey (NHANES). The relationships among inflammatory biomarkers (SIRI, SII, MLR, NLR, and PLR), hyperuricemia and CKD were assessed by multivariate logistic regression models. Restricted cubic splines (RCS) and segmented regression models were used to evaluate the nonlinear relationships. The diagnostic performance was evaluated using receiver operating characteristic (ROC) curve, and incremental predictive value was further calculated by Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI). The interaction analysis was performed to explore the combined effects.</p><p><strong>Results: </strong>SIRI, SII, MLR, and NLR were significantly linked with CKD. MLR exhibited a threshold effect at 0.22 (<i>p</i>-non-linear < 0.05), with significantly stronger association with CKD above this cutoff. SIRI demonstrated the best diagnostic accuracy among these biomarkers. Significant interactions were observed between hyperuricemia and inflammatory biomarkers (SIRI, SII, MLR, NLR), indicating that the association between inflammatory biomarkers and CKD is more pronounced in the presence of hyperuricemia.</p><p><strong>Conclusion: </strong>There were significant associations between inflammatory biomarkers (SII, SIRI, NLR, MLR) and CKD, with particularly stronger correlations observed in patients with hyperuricemia.</p>\",\"PeriodicalId\":20839,\"journal\":{\"name\":\"Renal Failure\",\"volume\":\"47 1\",\"pages\":\"2553808\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416012/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Renal Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/0886022X.2025.2553808\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Renal Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/0886022X.2025.2553808","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
The relationship among inflammatory biomarkers, hyperuricemia and chronic kidney disease: analysis of the NHANES 2015-2020.
Background: Inflammation and hyperuricemia are closely associated with chronic kidney disease (CKD). The systemic inflammation response index (SIRI), systemic immune-inflammation index (SII), monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are emerging as novel biomarkers. While, the synergistic effects of these biomarkers with hyperuricemia on CKD remain unclear.
Method: We analyzed 10,226 participants from 2015-2020 National Health and Nutrition Examination Survey (NHANES). The relationships among inflammatory biomarkers (SIRI, SII, MLR, NLR, and PLR), hyperuricemia and CKD were assessed by multivariate logistic regression models. Restricted cubic splines (RCS) and segmented regression models were used to evaluate the nonlinear relationships. The diagnostic performance was evaluated using receiver operating characteristic (ROC) curve, and incremental predictive value was further calculated by Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI). The interaction analysis was performed to explore the combined effects.
Results: SIRI, SII, MLR, and NLR were significantly linked with CKD. MLR exhibited a threshold effect at 0.22 (p-non-linear < 0.05), with significantly stronger association with CKD above this cutoff. SIRI demonstrated the best diagnostic accuracy among these biomarkers. Significant interactions were observed between hyperuricemia and inflammatory biomarkers (SIRI, SII, MLR, NLR), indicating that the association between inflammatory biomarkers and CKD is more pronounced in the presence of hyperuricemia.
Conclusion: There were significant associations between inflammatory biomarkers (SII, SIRI, NLR, MLR) and CKD, with particularly stronger correlations observed in patients with hyperuricemia.
期刊介绍:
Renal Failure primarily concentrates on acute renal injury and its consequence, but also addresses advances in the fields of chronic renal failure, hypertension, and renal transplantation. Bringing together both clinical and experimental aspects of renal failure, this publication presents timely, practical information on pathology and pathophysiology of acute renal failure; nephrotoxicity of drugs and other substances; prevention, treatment, and therapy of renal failure; renal failure in association with transplantation, hypertension, and diabetes mellitus.